Dr. West on FDA Approval of Brigatinib in ALK+ NSCLC

Name: Dr. West on FDA Approval of Brigatinib in ALK+ NSCLC
Uploaded: 2017-05-02T01:12:34.000Z
Description: H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the FDA approval of brigatinib (Alunbrig) as a treatment for patients with metastatic ALK-positive non–small cell lung cancer (NSCLC) who are resistant to prior crizotinib (Xalkori).

May 1, 2017

H. Jack West, MD

Video

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the FDA approval of brigatinib (Alunbrig) as a treatment for patients with metastatic ALK-positive non–small cell lung cancer (NSCLC) who are resistant to prior crizotinib (Xalkori).

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the FDA approval of brigatinib (Alunbrig) as a treatment for patients with metastatic ALK-positive non—small cell lung cancer (NSCLC) who are resistant to prior crizotinib (Xalkori).